From: Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review
vaccine
clinical benefit rate
s.c
73/215(34.0%)
i.m
16/80(20.0%)
i.d
31/120(25.0%)
i.v
15/76(19.7%)